Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (6): 1135-1139. doi: 10.19723/j.issn.1671-167X.2020.06.025
Previous Articles Next Articles
CLC Number:
| [1] |
Croia C, Bursi R, Sutera D, et al. One year in review 2019: pathogenesis of rheumatoid arthritis[J]. Clin Exp Rheumatol, 2019,37(3):347-357.
pmid: 31111823 |
| [2] |
Ottaviani S, Ayral X, Dougados M, et al. Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature[J]. Semin Arthritis Rheum, 2011,40(6):539-546.
doi: 10.1016/j.semarthrit.2010.07.005 pmid: 20884045 |
| [3] |
Hirose I, Mori Y, Fujimoto A. Case report: rheumatoid arthritis occurring during observation after surgery for localized pigmented villonodular synovitis[J]. Mod Rheumatol, 2003,13(3):281-284.
pmid: 24387219 |
| [4] |
Zhao X, Ji W, Qian X, et al. Pigmented villonodular synovitis developing in a patient with rheumatoid arthritis[J]. J Clin Rheumatol, 2014,20(5):283-286.
doi: 10.1097/RHU.0000000000000119 pmid: 25036563 |
| [5] |
Dougados M. Synovial fluid cell analysis[J]. Baillieres Clin Rheumatol, 1996,10(3):519-534.
pmid: 8876957 |
| [6] | Myers BW, Masi AT. Pigmented villonodular synovitis and tenosynovitis: A clinical epidemiologic study of 166 cases and literature review[J]. Medicine (Baltimore), 1980,59(3):223-238. |
| [7] |
Mastboom M, Verspoor F, Verschoor A, et al. Higher incidence rates than previously known in tenosynovial giant cell tumors[J]. Acta orthopaedica, 2017,88(6):688-694.
doi: 10.1080/17453674.2017.1361126 pmid: 28787222 |
| [8] |
Fiocco U, Sfriso P, Lunardi F, et al. Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis[J]. Autoimmun Rev, 2010,9(11):780-784.
doi: 10.1016/j.autrev.2010.07.001 pmid: 20620241 |
| [9] |
Gouin F, Noailles T. Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis)[J]. Orthop Traumatol Surg Res, 2017,103(1S):S91-S97.
doi: 10.1016/j.otsr.2016.11.002 pmid: 28057477 |
| [10] |
Staals E, Ferrari S, Donati D, et al. Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives[J]. Eur J Cancer, 2016,63:34-40.
doi: 10.1016/j.ejca.2016.04.022 pmid: 27267143 |
| [11] |
Cupp J, Miller M, Montgomery K, et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides[J]. Am J Surg Pathol, 2007,31(6):970-976.
doi: 10.1097/PAS.0b013e31802b86f8 pmid: 17527089 |
| [12] |
Oliviero F, Galozzi P, Ramonda R, et al. Unusual findings in synovial fluid analysis: A review[J]. Ann Clin Lab Sci, 2017,47(3):253-259.
pmid: 28667024 |
| [13] | 列锐锋. 膝关节色素沉着绒毛结节性滑膜炎MRI表现[J]. 罕少疾病杂志, 2020,27(2):67-69. |
| [14] |
Houdek MT, Scorianz M, Wyles CC, et al. Long-term outcome of knee arthroplasty in the setting of pigmented villonodular synovitis[J]. Knee, 2017,24(4):851-855.
doi: 10.1016/j.knee.2017.04.019 pmid: 28552192 |
| [15] |
Barile A, Sabatini M, Iannessi F, et al. Pigmented villonodular synovitis (PVNS) of the knee joint: magnetic resonance imaging (MRI) using standard and dynamic paramagnetic contrast media. Report of 52 cases surgically and histologically controlled[J]. Radiol Med, 2004,107(4):356-366.
pmid: 15103287 |
| [16] | 巫娟, 徐钢, 傅静. 膝关节色素沉着绒毛结节性滑膜炎的临床病理分析[J]. 四川医学, 2017,38(9):1010-1013. |
| [17] |
Bernthal N, Ishmael C, Burke Z. Management of pigmented villonodular synovitis (PVNS): an orthopedic surgeon’s perspective[J]. Curr Oncol Rep, 2020,22(6):63.
pmid: 32494892 |
| [18] |
Palmerini E, Staals E, Maki R, et al. Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors[J]. Eur J Cancer, 2015,51(2):210-217.
doi: 10.1016/j.ejca.2014.11.001 pmid: 25465190 |
| [19] |
Tap W, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial[J]. Lancet, 2019,394(10197):478-487.
doi: 10.1016/S0140-6736(19)30764-0 pmid: 31229240 |
| [20] |
Monestime S, Lazaridis D. Pexidartinib (TURALIO?): The first FDA-indicated systemic treatment for tenosynovial giant cell tumor[J]. Drugs R D, 2020,20(3):189-195.
doi: 10.1007/s40268-020-00314-3 pmid: 32617868 |
| [21] |
Gelderblom H, Cropet C, Chevreau C, et al. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2018,19(5):639-648.
doi: 10.1016/S1470-2045(18)30143-8 pmid: 29571946 |
| [1] | Hui WEI, Jingfeng ZHANG, Zhongqiang YAO, Jinxia ZHAO. Clinical characteristics and relevant factors of rheumatoid arthritis patients with anemia of chronic disease [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 307-312. |
| [2] | Tao WU, Jianzi LIN, Yafeng ZHU, Jianda MA, Peiwen JIA, Lijuan YANG, jie PAN, Yaowei ZOU, Ying YANG, Ye LU, Lie DAI. Serum inter-alpha-trypsin inhibitor heavy chain H3 is identified as a potential biomarker for myopenia in patients with rheumatoid arthritis using proteomic profiling [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1024-1031. |
| [3] | Yan DING, Lifang WANG, Chaoran LI, Zhemin LU, Lianjie SHI. Rheumatoid arthritis combined with IgG4-related disease successfully treated with rituximab: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1203-1207. |
| [4] | Ju YANG, Jing XU, Juhua DAI, Lianjie SHI. Expression of lumican protein in serum of patients with rheumatoid arthritis and its correlation with disease and immune activities [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 911-918. |
| [5] | Lianghua FENG, Lirong HONG, Yujia CHEN, Xueming CAI. Role and mechanism of ubiquitin-specific protease 35 in ferroptosis of rheumatoid arthritis-fibroblast like synoviocytes [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 919-925. |
| [6] | Peiwen JIA, Ying YANG, Yaowei ZOU, Zhiming OUYANG, Jianzi LIN, Jianda MA, Kuimin YANG, Lie DAI. Clinical characteristics of overlapping syndromes of low muscle mass in patients with rheumatoid arthritis and their impact on physical function [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1009-1016. |
| [7] | Doudou MA, Zhemin LU, Qian GUO, Sha ZHU, Jin GU, Yan DING, Lianjie SHI. Successful treatment of rheumatoid arthritis complicated with myasthenia gravis with low-dose rituximab: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1110-1114. |
| [8] | Rui YAN, Dan KE, Yan ZHANG, Li LI, Huanran SU, Wei CHEN, Mingxia SUN, Xiaomin LIU, Liang LUO. Diagnostic significance of serum chemokine CXCL-10 and Krebs von den lungen-6 level in patients with rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 956-962. |
| [9] | Liang ZHAO, Chenglong SHI, Ke MA, Jing ZHAO, Xiao WANG, Xiaoyan XING, Wanxing MO, Yirui LIAN, Chao GAO, Yuhui LI. Immunological characteristics of patients with anti-synthetase syndrome overlap with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 972-979. |
| [10] | Yijun HAN, Xiaoli CHEN, Changhong LI, Jinxia ZHAO. Application status of methotrexate in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 994-1000. |
| [11] | Dongwu LIU, Jie CHEN, Mingli GAO, Jing YU. Rheumatoid arthritis with Castleman-like histopathology in lymph nodes: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 928-931. |
| [12] | Huina HUANG,Jing ZHAO,Xiangge ZHAO,Ziran BAI,Xia LI,Guan WANG. Regulatory effect of lactate on peripheral blood CD4+ T cell subsets in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 519-525. |
| [13] | Xiaofei TANG,Yonghong LI,Qiuling DING,Zhuo SUN,Yang ZHANG,Yumei WANG,Meiyi TIAN,Jian LIU. Incidence and risk factors of deep vein thrombosis in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 279-283. |
| [14] | Xue ZOU,Xiao-juan BAI,Li-qing ZHANG. Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1013-1021. |
| [15] | Qi WU,Yue-ming CAI,Juan HE,Wen-di HUANG,Qing-wen WANG. Correlation between dyslipidemia and rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 982-992. |
|
||